43rd week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150297498 | ORGANOPOLYSILOXANE GRAFT POLYMER - The present invention relates to an organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived polymer segment as a side chain thereof, in which a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is not less than 35% by mass and not more than 70% by mass, and the unsaturated monomer-derived polymer segment contains a repeating unit derived from a nonionic unsaturated monomer having a glass transition temperature Tg of 60° C. or higher (except for a repeating unit derived from an unsaturated monomer containing an amino group) in an amount of not less than 40% by mass and not more than 90% by mass, and further contains a repeating unit derived from a cationic unsaturated monomer in an amount of not less than 10% by mass and not more than 60% by mass. | 2015-10-22 |
20150297499 | MAKE UP KIT COMPRISING A BASE COMPOSITION RESISTANT TO MAKE UP REMOVAL - The present invention relates to a kit for make-up and/or care of nails and/or false nails, comprising: —a composition C1 for make-up and/or care of nails and/or false nails comprising at least one film-forming polymer, said polymer being insoluble in acetone, methyl acetate, and ethyl acetate, and—a make-up removal composition C2 comprising at least one volatile solvent S2 selected from the group consisting of C | 2015-10-22 |
20150297500 | Surfactant Systems for Zinc Containing Compositions - Disclosed are oral care compositions comprising an orally acceptable vehicle, a basic amino acid in free or salt form, particles of precipitated calcium carbonate, a source of zinc ions, and a surfactant system selected from at least one of a poloxamer nonionic surfactant and a betaine zwitterionic surfactant or a mixture thereof. | 2015-10-22 |
20150297501 | COMPOSITION - A solid cosmetic composition includes (i) an outer layer having (a) a hard vegetable butter in an amount of 10 to 45 wt. % based on the outer layer, and (b) a soft vegetable butter in an amount of 55 to 80 wt. % based on the outer layer. The composition also includes an (ii) inner core which is (a) a soft vegetable butter composition; (b) a fondant; or (c) a liquid cosmetic. | 2015-10-22 |
20150297502 | Cosmeceutical Formulations of Natural Ingredients for Hair Growth - The invention relates to a cosmeceutical composition comprising of natural ingredients which is useful as a topical formulation for improving the growth of human hair. The invention also provides a method for preparing the said composition as well as the suitable applications of the said composition. | 2015-10-22 |
20150297503 | Composition For Preventing Dental Erosion - The present invention relates to a composition for use in preventing dental erosion, comprising a concentrate or extract of at least one plant selected from the family of Rosaceae, Grossulariaceae, and Lamiaceae and the use of a composition comprising a concentrate or extract of at least one plant selected from the family of Rosaceae, Grossulariaceae, and Lamiaceae for dental care. | 2015-10-22 |
20150297504 | COSMETIC USE OF A CAROB SEED EXTRACT AS A SLIMMING ACTIVE AGENT - Cosmetic methods for obtaining a slimming effect are disclosed. The methods include providing a composition containing a carob ( | 2015-10-22 |
20150297505 | ANTI-AGING COSMETIC COMPOSITION INCLUDING LIPID-SOLUBLE FRACTION OF BEE VENOM AND METHODS FOR PREPARING THE SAME - The present invention relates to a skin anti-aging cosmetic using bee venom. More specifically, the present invention relates to a cosmetic composition including lipid-soluble ingredients of bee venom. The cosmetic composition includes a lipid-soluble fraction and a water-soluble fraction obtained by fractionation of bee venom with a lipid-soluble solvent and a water-soluble solvent, respectively. The lipid-soluble fraction and the water-soluble fraction are in a volume ratio of 1:0.01-0.5. The cosmetic composition has anti-aging effects, such as reduction of skin wrinkles | 2015-10-22 |
20150297506 | USE OF PROBIOTIC MICRO-ORGANISMS AS AN AGENT THAT PROMOTES THE SYNTHESIS OF MELANIN - The present invention relates to the oral use of | 2015-10-22 |
20150297507 | DICLOFENAC FORMULATIONS - The subject invention provides improved diclofenac gel formulations. | 2015-10-22 |
20150297508 | Topical Formulation to Enhance Genital Sensation and Function - A topical formulation that functions to enhance genital sensation and function can be utilized by either male or female users. The topical formulation incorporates active compounds which function cooperatively to stimulate nerve activity, enhancing sensitivity, and facilitating tumescence in order to increase pleasure from physical stimulation and orgasms. It has incorporated various compounds that provide energy and support energy production in a cell, that stimulate nerve activity and sensitivity, that support blood flow and/or vasodilation to a bodily region, that support penetration and transport of active compounds, and that preserve the efficaciousness, effectively dilute, serve as a carrier. | 2015-10-22 |
20150297509 | IMPLANTABLE DRUG DELIVERY COMPOSITIONS AND METHODS OF TREATMENT THEREOF - Reservoir-based drug delivery compositions comprise an API (e.g., raloxifene, pramipexole, or lidocaine), methods of delivering the API from an implantable composition in a therapeutically effective amount to a subject, methods of treatment, subcutaneous delivery systems, and kits regarding the same. The reservoir-based drug delivery compositions may be implanted in order to deliver a therapeutically effective amount of the API to the subject for long periods of time (e.g., at least one month, at least six months, at least one year, at least 18 months, at least two years, at least 30 months, etc.). The therapeutically effective amount of API may be delivered at a pseudo-zero order rate (e.g., zero order rate). | 2015-10-22 |
20150297510 | DHEA BIOADHESIVE CONTROLLED RELEASE GEL - The DHEA bioadhesive controlled release gel includes DHEA mixed in a polymeric gel for the purpose of treating atrophic vaginitis, vaginal dryness, dyspareunia, itching, burning, irritation, increase in pH and decreased vaginal flora. The gel adheres to vaginal tissue and protects the DHEA from systemic absorption, which prevents leakage, loss of DHEA, and elevated levels of systemic DHEA. The gel is configured to slowly erode over time so as to deliver a predetermined dose of DHEA to vaginal tissue and thereby promote local intracellular conversion to estrogens, androgens and progesterone so that normal levels of fluid in the vagina is produced. The gel also acts as a moisturizer. An adjustable applicator may also be provided to insure proper placement and dose of the DHEA. | 2015-10-22 |
20150297511 | OPHTHALMIC COMPOSITIONS WITH ALKOXYLATED NATURAL WAXES - Ophthalmic compositions comprising 0.005 wt. % to 2.0 wt. % of alkoxylated natural waxes selected from the group consisting of alkoxylated lanolin and alkoxylated jojoba, and a method of treating a patient diagnosed with dry eye syndrome, or for cleaning and disinfecting contact lenses, with the ophthalmic compositions. | 2015-10-22 |
20150297512 | LOCAL ADMINISTRATION-TYPE PHARMACEUTICAL FOR IMPROVING DYSPHAGIA - A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition. | 2015-10-22 |
20150297513 | INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF KIDNEY DISEASE AND PREPARATION METHOD THEREOF - The present invention provides an inhalation-type pharmaceutical composition for kidney disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising corticosteroid, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, erythropoietin, phosphate binding agent, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user. | 2015-10-22 |
20150297514 | INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LUNG CANCER AND PREPARATION METHOD THEREOF - The present invention provides an inhalation-type pharmaceutical composition for lung cancer and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising cisplatin, docetaxel, etoposide, gefitinib, erlotinib, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user. | 2015-10-22 |
20150297515 | INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HYPERTENSION AND PREPARATION METHOD THEREOF - The present invention provides an inhalation-type pharmaceutical composition for hypertension and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising propranolol, captopril, amlodipine besylate, losartan, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user. | 2015-10-22 |
20150297516 | INHALATION-TYPE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES AND PREPARATION METHOD THEREOF - The present invention provides an inhalation-type pharmaceutical composition for diabetes and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising metformin hydrochloride, glibenclamide, glucobay, rosiglitazone maleate, insulin, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user. | 2015-10-22 |
20150297517 | NEW STABLE ANESTHETIC COMPOSITION FOR REDUCING SKIN REACTIONS - A composition is described with reduced degradation rate and/or improved stability of its components. The composition can alleviate or even annihilate cutaneous reactions and can include an emulsion with an oil phase and an aqueous phase, wherein the oil phase can be a eutectic mixture of at least one anesthetic compound and at least one adrenergic receptor agonist. Methods of using such a composition are also described. | 2015-10-22 |
20150297518 | FOAMABLE FORMULATION - The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen. | 2015-10-22 |
20150297519 | IN VITRO RELEASE ASSAY FOR LIPOSOME ENCAPSULATED VINCRISTINE - The present invention provides a novel in vitro release assay for the accurate, reproducible quantitation of vincristine sulfate release from liposomes. | 2015-10-22 |
20150297520 | MEDICAMENT-CONTAINING HOLLOW PARTICLE - The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer. | 2015-10-22 |
20150297521 | Pharmaceutical Core-Shell Composite Powder and Processes for Making the Same - A composite particle including a core with at least one carrier material; a fluidizing material layer on the surface of the core; and an outer layer comprising nanoparticles of an ingestible material distributed in at least one matrix-forming material. A process of making the composite particles includes the steps of dry coating carrier particles with a fluidizing material; preparing a suspension of nanoparticles of an ingestible material distributed in a matrix-forming material; and fluid bed coating the carrier particles with the suspension. The process and products provide quick dissolving composite particles which can be used for delivery of poorly water soluble ingestible materials in suitable dosage forms. The process of the invention reduces or prevents particle agglomeration during fabrication of the composite particles to enable delivery and quick redispersion of nanoparticles of the ingestible material from a dosage form. | 2015-10-22 |
20150297522 | PROCESS FOR THE PRODUCTION OF DISCRETE SOLID EXTRUDED PARTICLES - The present invention relates to a process for the production of discrete solid extruded particles comprising emulsion droplets, to such particles as well as to the use of such particles in food, feed, pharmaceutical and personal care applications. | 2015-10-22 |
20150297523 | PHARMACEUTICAL COMPOSITION COMPRISING BENDAMUSTINE - The present invention relates to a pre-lyophilized composition comprising bendamustine or its pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, an organic solvent and water. Furthermore, the present invention provides a stable pharmaceutical composition comprising bendamustine hydrochloride prepared from such pre-lyophilized composition, a process for preparing such composition; and its use in the treatment of cancer. | 2015-10-22 |
20150297524 | LYOPHILIZATION OF SYNTHETIC LIPOSOMAL PULMONARY SURFACTANT - Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described. | 2015-10-22 |
20150297525 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 2015-10-22 |
20150297526 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HIV INFECTION - The invention is a pharmaceutical composition for the treatment of HIV infection; containing at least one HIV protease inhibitor as an active ingredient, as well as pharmaceutically acceptable excipients with a specific quantitative component ratio. Additionally, the invention belongs to the process of its production and to a treatment method. The inventive pharmaceutical composition has increased bioavailability and improved technological properties, such as durability, plasticity, disintegration, compared to the prototype drug. | 2015-10-22 |
20150297527 | Pharmaceutical Compositions - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 2015-10-22 |
20150297528 | Hydroxypropyl Starch Vacant Capsules And A Process For Producing Them - This present invention discloses hydroxypropyl starch vacant capsules and a process for producing them, wherein said hydroxypropyl starch vacant capsules are made of hydroxypropyl starch and water and optional light-screening agent, colorant, aromatics, and flavoring agent through the processes of raw material mixup, gelatinization, stabilization, and capsule-forming. The hydroxypropyl starch capsules disclosed in this invention have such advantages as extensive source of raw material, high safety level, disintegrating property and friability over the products prepared through existing technologies. | 2015-10-22 |
20150297529 | PHARMACEUTICAL COMPOSITION - Shelf life of soft gelatin capsules comprising a soft gelatin shell encapsulating a pharmaceutical formulation comprising cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form in an amount from 25 wt % to 99 wt % of the formulation and cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount from 1 wt % to 75 wt % of the formulation in which the gelatin component of the shell is Type B gelatin, is improved by replacing up to 75 wt % of the gelatin component with porcine Type A gelatin. | 2015-10-22 |
20150297530 | FIXED DOSE COMBINATION THERAPY OF PARKINSON'S DISEASE - A pharmaceutical composition for use in treatment of Parkinson's disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline, wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline, and the dose of pramipexole is lower than or equal to the dose of rasagiline. | 2015-10-22 |
20150297531 | NANOPARTICLE FORMULATIONS WITH ENHANCED MUCOSAL PENETRATION - Hypotonic formulations were evaluated for delivering water-soluble drugs and for drug delivery with muco-inert (that is, non-adhesive) mucus-penetrating nanoparticles (MPP). Hypotonic formulations markedly increased the rate at which drugs and MPP reached the epithelial surface, including deep into the vaginal folds. Minimally hypotonic formulations, preferably ranging from 20-220 mOsm/kg, provided rapid and uniform delivery of MPP to the entire vaginal surface, with minimal risk of epithelial toxicity. Data also show that there is a higher osmolality in the colon, such that vehicles with an osmolality above that of blood plasma (generally considered isotonic at ˜300 mOsm/kg), still lead to improvements in distribution in the colon due to rapid, osmotically-induced fluid absorption. The range for improved colon distribution with a hypotonic vehicle in the colon is ˜20 mOsm/kg-450 mOsm/kg. | 2015-10-22 |
20150297532 | Ropinirole-Containing Adhesive Patch - A patch containing free ropinirole (ropinirole in free form) in an adhesive base is provided, in which the patch exhibits favorable and continuous transdermal absorbability, high drug stability, and excellent adhesiveness. A transdermal absorption patch includes free ropinirole added to an adhesive base that contains a styrene-isoprene-styrene block copolymer (SIS), one or two or more tackifier resins containing a rosin-based resin, and a softener. The transdermal absorption patch is characterized in that the compounding ratio of the rosin-based resin to the free ropinirole represented as the ratio of the weight of the combined rosin-based resin to the free ropinirole is 3.5 to 8.0. In particular, a ropinirole-containing patch wherein the rosin-based resin is a hydrogenated rosin glycerol ester and the softener is liquid paraffin is provided. | 2015-10-22 |
20150297533 | Visual Performance and/or Macular Pigmentation - Disclosed is a composition comprising MZ for use as a dietary supplement or food additive for oral consumption for improving the visual performance of a human subject. | 2015-10-22 |
20150297534 | METHODS AND COMPOSITIONS FOR THE MEDIATION OF NSAID-INDUCED REACTIONS - Administration of an NSAID with at least one dual inhibitor of mPGES-1 and NF-κB plus at least one zwitterionic phospholipid rests in a lessening of side effects and the ability to administer smaller doses of an NSAID without loss of effectiveness. | 2015-10-22 |
20150297535 | FORMULATIONS OF DIMETHYL TRISULFIDE FOR USE AS A CYANIDE ANTIDOTE - Dimethyl trisulfide antidote compositions may be used to as a cyanide poisoning antidote. Formulations of dimethyl trisulfide may be made in an aqueous solvent system that includes water and one or more of a co-solvent, a surfactant, a cyclodextrin, and a phospholipid. | 2015-10-22 |
20150297536 | CURCUMIN COMPOSITIONS AND USES THEREOF - Curcumin compositions herein are described for improving muscle performance, endurance capacity and resistance to fatigue, when administered in effective amounts to a subject in need of such improvement. The compositions are comprised of curcumin and at least one pharmaceutically and/or nutraceutically acceptable excipient such as a hydrophilic carrier and exhibit enhanced bioavailability. More particularly methods are described and include use of curcumin compositions to increase exercise time, performance and capacity and to prevent muscle soreness, fatigue and injury. The compositions enhance mitochondrial biogenesis by modulating mitochondrial function, increasing mitochondrial mass and oxygen consumption, thus increasing mitochondrial aerobic capacity. The compositions reduce oxidative muscle stress, by decreasing inflammatory cytokines and inflammatory markers. Curcumin compositions are safe for consumption for pharmaceutical and/or nutraceutical purposes and are prepared by economic methods using conventional equipments and can be effectively used for enhancing muscle and exercise performance. | 2015-10-22 |
20150297537 | Compositions for the Treatment of CNS-Related Conditions - The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine. | 2015-10-22 |
20150297538 | Intravenous Administration of Tramadol - A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours. | 2015-10-22 |
20150297539 | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes - The present invention relates to a composition comprising, in combination, metformin or a salt thereof, a pharmaceutically acceptable carrier or excipient and at least one compound of formula (I), the enantiomers, diastereoisomers or pharmaceutically acceptable salts thereof. Formula (I). The present invention also relates to the use of said composition for the treatment of diseases associated with insulin resistance syndrome. | 2015-10-22 |
20150297540 | Uses and Methods for the Treatment of Liver Diseases or Conditions - The present application relates methods and uses of oral diamidines or pharmaceutically acceptable salts thereof for the treatment of liver diseases or conditions. | 2015-10-22 |
20150297541 | COMPOSITION AND METHOD FOR EXTERMINATING ANIMAL PARASITE - A composition for exterminating an animal parasite, the composition including, as an active ingredient, at least one of 3-aminoxalylaminobenzamide derivatives represented by the following Formula (1): | 2015-10-22 |
20150297542 | Powder composition for disinfection of the teats of dairy animals - A powder composition for the post-milking teat disinfection of dairy animals is described. In particular, said composition has proven to be advantageously effective as bactericidal agent, while without causing irritation or reddening of the skin. | 2015-10-22 |
20150297543 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 2015-10-22 |
20150297544 | COMPOSITIONS FOR IMPROVEMENT OF BRAIN FUNCTION - A composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and one or more enzymes selected from a group consisting of a lipase, a protease and an amylase, and medical uses thereof in, neurological and/or neurodegenerative disease, neurological trauma, depression or chronic fatigue syndrome. | 2015-10-22 |
20150297545 | ORGANIC ACIDS AS AGENTS TO DISSOLVE CALCIUM MINERALS IN PATHOLOGICAL CALCIFICATION AND USES THEREOF - In an embodiment of the present disclosure, there is provided a composition for dissolving calcium oxalate crystals thereby inhibiting/preventing further growth of crystals. In some embodiments, such a composition comprises at least one stereoisomer of hydroxycitrate, a derivative of the organic acid citrate. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. | 2015-10-22 |
20150297546 | BLOOD FLOW PROMOTING AGENT - The present invention provides a blood flow promoting agent containing citrulline or a salt thereof and capsaicin or capsaicinoids as active ingredients, which is safe even by long-term administration, a food with health claims and a functional food affording such action, particularly, a blood flow promoting agent exhibiting an effective vasodilatory action of capsaicin at a low dose free of irritant property, which can be applied to improvement of athletic performance exhibited in relation to peripheral vasodilatation, suppression of fat accumulation, improvement of skin quality, as well as securing blood circulation in ischemic disease and the like, relaxation of blood vessel biased to coarctation due to advancing age, lifestyle-related diseases and the like, prophylaxis of arteriosclerosis, and prophylaxis of stiff neck, feeling of cold, erectile dysfunction, thrombosis and the like due to blood flow disorder. | 2015-10-22 |
20150297547 | SMALL MOLECULE SUBSTANCE FOR IMPROVING SENSITIVITY OF BACTERIA TO ANTIBIOTICS - Disclosed is a new function of a small molecule metabolite glutamine. The small molecule can improve sensitivity of bacteria including antibiotic-resistant bacteria to antibiotics. Also disclosed is an application of glutamine in combination with glucose in improving sensitivity of bacteria to antibiotics. | 2015-10-22 |
20150297548 | ALPHA-DERIVATIVES OF CIS-MONOUNSATURATED FATTY ACIDS FOR USE AS MEDICINES - Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines. | 2015-10-22 |
20150297549 | COMPOSITION COMPRISING A COMBINATION OF DHA AND EPA FOR ADMINISTRATION PRIOR TO COMMENCEMENT OF CHEMOTHERAPY - The invention relates to a composition comprising a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The composition can be used for enhancing the activity of chemotherapy or radiotherapy and/or in the prevention or reduction of side effects caused by the chemotherapy or radiotherapy in a patient ill with cancer, the composition being intended for administration to the patient prior to the commencement of a cycle of chemotherapy or radiotherapy. | 2015-10-22 |
20150297550 | SUSTAINED RELEASE OF TOPICAL ANESTHETICS - A composition and method to alleviate oral mucosal discomfort and irritation in an orthodontic patient. A wax matrix containing less that 15% analgesic/anesthetic agent such as benzocaine and excipients enhanced and extended release of the analgesic/anesthetic agent compared to known art formulations. The composition exhibited desirable aesthetic properties, was easy to apply, and the relatively lower concentration of active agent provided enhanced safety. | 2015-10-22 |
20150297551 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 2015-10-22 |
20150297552 | FERTILITY ENHANCING AGENT - Present invention relates to the field of medicine, in particular, to adrology and is also useful in veterinary medicine for treating mammals having impaired fertility. The invention provides a fertility enhancing drug, wherein the drug is a clathrate complex of β-cyclodextrine with 9-phenyl-sym-octahydroselenoxanthene in α-crystalline form represented by structural formula. Technical effect provided by present invention consists in improvement of pregnancy and fertility parameters. 6 tables. | 2015-10-22 |
20150297553 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL - The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol. | 2015-10-22 |
20150297554 | TRANSMUCOSAL TAXANE COMPOSITION - The present invention provides a pharmaceutical composition for delivering an active agent taxane through transmucosal administration, more particularly through the buccal mucosa or sublingual mucosa. The present invention provides a method for treating cancer by buccal or sublingual administration of the pharmaceutical composition to a subject. The pharmaceutical composition comprises a taxane, a non-ionic surfactant, a viscosity enhancing agent, an adhesive agent, and an alcohol solvent at pH 4-6. | 2015-10-22 |
20150297555 | COMBINATION THERAPEUTICS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASES - Embodiments of the present invention are directed to the administration of bryostatins and bryostatins and retinoids for the treatment of disease responsive to increases in alpha secretase activity. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma. | 2015-10-22 |
20150297556 | TRANSDERMAL CANNABINOID PATCH - The present invention includes a transdermal patch which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The patch may comprise the following components: a backing; and a skin-adhesive polymer matrix attached to one side of the backing, which includes a cannabinoid, a carrier agent, a terpene, and a permeation agent. The cannabinoid is capable of diffusing from the matrix in the transdermal patch into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia. | 2015-10-22 |
20150297557 | Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, Including Mast Cell Related Disorders - Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided. | 2015-10-22 |
20150297558 | Artemisinin And Its Derivatives For Use In The Treatment Of Trauma Haemorrhage And Associated Conditions - The present invention relates to the treatment of trauma haemorrhage or trauma haemorrhage-induced organ injury and associated disorders (in particular stoke, burns and brain injury) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the treatment of myocardial infarction and coronary heart disease (and associated disorders) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the use of artemisinin and its derivatives in coronary artery bypass surgery, heart transplantation, and diseases associated with ischaemia-reperfusion. | 2015-10-22 |
20150297559 | METHODS AND COMPOSITIONS FOR TREATMENT OF LIPID STORAGE DISORDERS - Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids. | 2015-10-22 |
20150297560 | USE OF OSTHOLE FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS - The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc. | 2015-10-22 |
20150297561 | Low Dose Lipoic Acid Pharmaceutical Compositions and Methods - Compositions containing low doses of lipoic acid-based active agents and methods for using the same are provided. In particular, compositions containing low dose lipoic acid, lipoic acid derivatives, said lipoic acid seleno-derivatives and are provided to prevent and/or treat ocular diseases. | 2015-10-22 |
20150297562 | ANALGESIC - An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing at least one member selected from a trans-2-decenoic acid derivative represented by the formula (1) and a pharmaceutically acceptable salt thereof as an active ingredient: | 2015-10-22 |
20150297563 | REJUVENATION OF PRECURSOR CELLS - The present invention relates generally to methods and pharmaceutical compositions for rejuvenating hematopoietic stem cells and progenitor cells from blood, intestinal tissue and dermal tissue by administration of at least one inhibitor of a GT-Pase, such as Cdc42 GTPase. | 2015-10-22 |
20150297564 | METHOD OF ENHANCING GLUCOSE-STIMULATED INSULIN SECRETION AND OF TREATING TYPE 2 DIABETES OR HYPOGLYCEMIA - The present invention is directed to a method of enhancing glucose-stimulated insulin secretion in a subject. The method involves selecting a subject with: (1) an antioxidant deficiency and (2) a need for enhanced glucose-stimulated insulin secretion, and administering to the selected subject an agent selected from the group consisting of (1) a compound according to Formula I or a pharmaceutically acceptable salt thereof: | 2015-10-22 |
20150297565 | PHENYLPYRAZOLE INJECTABLE COMPOSITIONS - This invention relates to a veterinary composition comprising a fluorinated cyclopropylphenylpyrazole. The veterinary composition also comprises a veterinary acceptable carrier including a triglyceride, a solvating agent and optionally an antioxidant. The compositions are injectable. The invention also relates to a method of treating an animal with a parasitic infestation by administering the veterinary composition to the animal in need thereof. | 2015-10-22 |
20150297566 | RORgammaT INHIBITORS - The present invention relates to compounds according to Formula I | 2015-10-22 |
20150297567 | TREATMENT FOR CHRONIC KIDNEY DISEASE - A method of treating chronic kidney disease by administering to a subject a composition that includes L-arginine, glycine, L-glutamine, L-histidine, L-aspartic acid L-glutamic acid, and L-carnosine. | 2015-10-22 |
20150297568 | Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein. | 2015-10-22 |
20150297569 | NOVEL SELENIUM-CONTAINING COMPOUND - The invention provides a method of improving an antioxidant effect in a redox pathway that involves selenium in a subject, an in vitro method of inhibiting oxidation in a cell or tissue, and an in vitro method of promoting proliferation of a cell, by use of a selenium-containing compound of chemical formula 1: | 2015-10-22 |
20150297570 | SMALL MOLECULE INHIBITORS OF MALT1 - MALT1 cleavage activity is linked to the pathogenesis of activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), a chemo-resistant form of DLBCL. We developed a MALT1 activity assay and identified chemically diverse MALT1 inhibitors. A selected lead compound MI-2 featured direct binding to MALT1 and suppression of its protease function. MI-2 concentrated within human ABC-DLBCL cells and irreversibly inhibited cleavage of MALT1 substrates. This was accompanied by suppression of NF- | 2015-10-22 |
20150297571 | Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists - The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A | 2015-10-22 |
20150297572 | Calcium Flux Agonists And Methods Therefor - Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca | 2015-10-22 |
20150297573 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL - The present invention relates to the use of a Tpl2 kinase inhibitor for preventing treating diabetes and promoting β-cell survival and function in a number of applications. | 2015-10-22 |
20150297574 | METHOD OF TREATING SKIN DISEASES - Acetylcholinesterase inhibitors, such as galantamine or donepezil, have been to be useful in the topical treatment of skin diseases and skin problems. | 2015-10-22 |
20150297575 | METHODS OF MODULATING FOLLICLE STIMULATING HORMONE ACTIVITY - Hedgehog pathway modulators, such as hedgehog pathway activators or inhibitors, and the use of such modulators to modulate FSH signaling are described. | 2015-10-22 |
20150297576 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer. | 2015-10-22 |
20150297577 | METHODS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS - The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against cancer stem cells. | 2015-10-22 |
20150297578 | Selective Targeting Agents for Mitochondria - The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the β-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. | 2015-10-22 |
20150297579 | TREATMENT OF CANCER WITH POMALIDOMIDE IN A RENALLY IMPAIRED SUBJECT - Provided herein are methods of treating, preventing, or managing one or more symptoms of a disease (e.g., cancer) in a subject with renal impairment, comprising administering to the subject pomalidomide. Also provided herein are methods of treating, preventing, or managing one or more symptoms of a disease (e.g., cancer) in a subject with renal impairment, comprising administering to the subject a therapeutically effective amount of pomalidomide and dexamethasone. | 2015-10-22 |
20150297580 | NICOTINE COMPOSITION - An inhalable composition comprising: nicotine or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric alcohol; and a glycol and/or glycol ether, characterised in that the ratio of monohydric alcohol:glycol or glycol ether by weight is from 6:1 to 1:1. | 2015-10-22 |
20150297581 | RHO KINASE INHIBITORS - Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds. | 2015-10-22 |
20150297582 | Methods for Novel Drug Discovery, Treatment And Selective Targeting for Gefitinib-Resistant Non-Small-Cell Lung Cancer Harboring T790M Mutation - The present invention relates to methods for novel drug discovery, treatment and selective targeting for Gefitinib-resistant non-small-cell lung cancer (NSCLC) harboring an additional mutation, in particular, to the discovery of a drug candidate or agent identified by the presently claimed method for use in treating and selective targeting Gefitinib-resistant NSCLC harboring T790M mutation. | 2015-10-22 |
20150297584 | LEARNING AND MEMORY IMPROVER - The present invention aims to provide antidementia agents which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide agents for improving learning and memory which are useful for improvement of learning and memory and can be ingested continuously. The present invention provides antidementia agents and agents for improving learning and memory, each comprising a cyclic dipeptide with the 2,5-diketopiperazine structure as an active ingredient. | 2015-10-22 |
20150297585 | COMPOSITIONS COMPRISING VORTIOXETINE AND DONEPEZIL - Pharmaceutical compositions comprising vortioxetine and donepezil are provided and the use of such composition for the treatment of cognitive dysfunctions. | 2015-10-22 |
20150297586 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES - This invention relates to the use of a compound in formula (I) and its salts acceptable pharmaceutically in preparation of vasodilative drugs: | 2015-10-22 |
20150297587 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES - Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed. | 2015-10-22 |
20150297588 | STERILE OTIC FORMULATIONS - The present disclosure describes a sterile formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, and antifungal, and an optional anti-inflammatory in a thick, otic carrier. In one embodiment, the sterilization comprises e-beam irradiating ingredients the formulation while heat-sterilizing other ingredients before combining under sterile condition. | 2015-10-22 |
20150297589 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 2015-10-22 |
20150297590 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY - Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer. | 2015-10-22 |
20150297591 | METHODS OF TREATING PULMONARY FIBROSIS - A method of treating ionizing radiation injury, or pulmonary fibrosis, or pulmonary hypertension due to any cause, such as idiopathic, autoimmune, or environmental, in a mammalian subject in need thereof, comprises administering the subject a gastrin-releasing peptide (GRP) blocking agent or inhibitor in a treatment effective amount. | 2015-10-22 |
20150297592 | COMPOSITION CONTAINING ECOTINE OR HYDROXYECOTINE AS AN ACTIVE SUBSTANCES FOR PROMOTING THE REGENERATION OF INJURED BODY TISSUE - The invention relates to a composition containing as active agent ectoine, hydroxyectoine, glucosylglycerol and/or salts, esters or amides of these compounds for promoting the regeneration of injured body tissue. The invention has special significance for the treatment of chronic wounds or ulcers. | 2015-10-22 |
20150297593 | INHIBITION OF VIRAL INFECTION-TRIGGERED ASTHMA WITH C-KIT INHIBITOR - The invention provides methods, compositions, and kits featuring a c-Kit kinase inhibitor for use in preventing or treating virus-induced respiratory pathology. | 2015-10-22 |
20150297594 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor - A pharmaceutical composition comprising 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof and N-((S)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide or a pharmaceutically acceptable salt and/or solvate thereof. | 2015-10-22 |
20150297595 | INHIBITORS OF SYK AND JAK PROTEIN KINASES - The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma. | 2015-10-22 |
20150297596 | ISOXAZOLINES AS THERAPEUTIC AGENTS - The present invention provides compound of Formula (I) | 2015-10-22 |
20150297597 | METHODS OF TREATMENT OF SKIN ULCERS - Methods for treating and/or preventing skin ulcers are provided featuring administration of pharmaceutical compositions comprising inhibitors of activity or expression of Lp-PLA | 2015-10-22 |
20150297598 | METHODS FOR TREATING RENAL DISEASE - The invention features methods for treating or reducing the likelihood of developing a renal disease by administering to a subject in need thereof an agent that decreases expression of a pathogenic APOL1. The agents of the method target various signaling pathways and decrease the level of the pathogenic APOL1 polypeptide. | 2015-10-22 |